Pipeline may offer options for combating diabetic eye disease

November 25, 2022

Intravitreally injected anti-VEGF drugs are undergoing investigation as researchers look for new treatment options.

Alcon finalizes deal to acquire Aerie Pharmaceuticals

November 22, 2022

According to the company, the deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.

Apellis reveals FDA acceptance of NDA amendment and new PDUFA date for pegcetacoplan for GA

November 18, 2022

The company noted the updated PDUFA goal date is February 26, 2023. The FDA also reiterated that they do not plan to hold an advisory committee meeting to discuss the application.

Belite Bio completes phase 3 clinical trial plans for LBS-008

November 18, 2022

According to the company, LBS-008 is an orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt disease and dry age-related macular degeneration.

FDA approves first treatment that can delay onset of Type 1 diabetes

November 18, 2022

Delaying the disease can also delay any onset of vision problems, including diabetic retinopathy and diabetic macular edema.

NeoLight rolls out ROP risk management software for pediatric ophthalmology

November 17, 2022

According to the company, ROP Check builds upon its pediatric retina screening portfolio, adding digital management (schedule, document, bill, and transfer) for treating patients with retinopathy of prematurity.

Leaders in academic ophthalmology discuss AI for eye screening

November 16, 2022

Artificial intelligence in a primary care and clinic settings increases the likelihood of catching diabetic retinopathy in underinsured patients, resulting in increased successful referrals.

Significance of periphery in diabetic retinopathy diagnosis and management

November 15, 2022

Being able to visualize and evaluate the retinal periphery provides a better understanding of the disease status and supports a better treatment decision.

Managing a challenging case of AMD and DME

November 13, 2022

David Eichenbaum, MD, FASRS, shared difficult cases of diabetic macular edema (DME) and age-related macular degeneration (AMD) and insights into patient care.

OPT-302 VEGF-C/D “trap” molecule for AMD promising in Phase 2b, moves to Phase 3

November 07, 2022

OPT-302 in combination with standard-of-care anti-VEGF-A agents shown to improve visual acuity, anatomic endpoints.